NCT06267092CompletedPhase 1
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months. Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 164 (actual)
- First submitted
- 12 Feb 2024
- Start date
- 15 Feb 2024
- Primary completion date
- 7 Apr 2025
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT06267092
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 164
- From 15 Feb 2024 to the primary completion date, 7 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of type 1 or type 2 diabetes mellitus
Lab values
- Glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) at screening
Other
- Contraindication for magnetic resonance scanning
- For Part B:
Who the study is looking for
- Male or female
- Aged 18-65 years (both inclusive) at the time of signing informed consent
- Right-handed as evaluated by the Edinburgh Handedness Inventory
- Body weight less than or equal to 180 kilogram at screening
- For Part A:
- A score of 7 or less on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire
- Body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) at screening
- For Part B:
- A score of 8 or more on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire
- Body mass index equal to or above 27.0 kilogram per meter square. Overweight should be due to excess adipose tissue, as judged by the investigator
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charité - Campus Charité Mitte - Charité Research Organisation GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.